ATE523196T1 - Mitotische kinesinhemmer und verfahren zu ihrer verwendung - Google Patents

Mitotische kinesinhemmer und verfahren zu ihrer verwendung

Info

Publication number
ATE523196T1
ATE523196T1 AT05819172T AT05819172T ATE523196T1 AT E523196 T1 ATE523196 T1 AT E523196T1 AT 05819172 T AT05819172 T AT 05819172T AT 05819172 T AT05819172 T AT 05819172T AT E523196 T1 ATE523196 T1 AT E523196T1
Authority
AT
Austria
Prior art keywords
methods
inhibitors
mitotic kinesin
kinesin inhibitors
pharmaceutical compositions
Prior art date
Application number
AT05819172T
Other languages
English (en)
Inventor
Jeremy Hans
Eli M Wallace
Qian Zhao
Joseph P Lyssikatos
Tom Aicher
Ellen Laird
John Robinson
Shelley Allen
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of ATE523196T1 publication Critical patent/ATE523196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/201—Esters of thiophosphorus acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT05819172T 2004-10-19 2005-10-18 Mitotische kinesinhemmer und verfahren zu ihrer verwendung ATE523196T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62004804P 2004-10-19 2004-10-19
US11/252,232 US7449486B2 (en) 2004-10-19 2005-10-17 Mitotic kinesin inhibitors and methods of use thereof
PCT/US2005/037305 WO2006044825A2 (en) 2004-10-19 2005-10-18 Mitotic kinesin inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE523196T1 true ATE523196T1 (de) 2011-09-15

Family

ID=36203637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819172T ATE523196T1 (de) 2004-10-19 2005-10-18 Mitotische kinesinhemmer und verfahren zu ihrer verwendung

Country Status (26)

Country Link
US (8) US7449486B2 (de)
EP (1) EP1809280B1 (de)
JP (4) JP5128283B2 (de)
KR (1) KR101280755B1 (de)
CN (4) CN101083988A (de)
AT (1) ATE523196T1 (de)
AU (1) AU2005295403B2 (de)
BR (1) BRPI0518228B8 (de)
CA (4) CA2584866C (de)
CY (1) CY1112238T1 (de)
DK (1) DK1809280T3 (de)
ES (1) ES2370774T3 (de)
HR (1) HRP20110764T1 (de)
IL (2) IL182417A0 (de)
ME (1) ME01950B (de)
MX (1) MX2007004547A (de)
NO (1) NO341725B1 (de)
NZ (1) NZ554306A (de)
PL (1) PL1809280T3 (de)
PT (1) PT1809280E (de)
RS (1) RS52037B (de)
RU (1) RU2426729C2 (de)
SI (1) SI1809280T1 (de)
TW (1) TWI357900B (de)
WO (1) WO2006044825A2 (de)
ZA (1) ZA200703168B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE480527T1 (de) * 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
ES2394850T3 (es) 2003-04-18 2013-02-06 Kyowa Hakko Kirin Co., Ltd. Inhibidor de cinesina mitótica
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
US7723365B2 (en) * 2004-08-18 2010-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
EP2081918A2 (de) * 2006-10-03 2009-07-29 Array Biopharma, Inc. Inhibitoren von mitotischem kinesin und verfahren zu deren anwendung
WO2008070739A1 (en) * 2006-12-06 2008-06-12 Cytokinetics, Inc. Ksp activators
CL2008003063A1 (es) * 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
KR20100075508A (ko) * 2007-11-09 2010-07-02 쉐링 코포레이션 Ｋｓｐ 키네신 활성 억제용 화합물
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
PL2349259T3 (pl) * 2008-10-16 2016-07-29 Array Biopharma Inc Inhibitory mitozy do zwiększania apoptozy w terapii
EP2430030A1 (de) * 2009-05-13 2012-03-21 Schering Corporation Spiro-1,3,4-thiadiazolinderivate als ksp-inhibitoren
NZ705058A (en) * 2010-03-12 2016-10-28 Omeros Corp Pde10 inhibitors and related compositions and methods
FR2991199B1 (fr) * 2012-05-30 2015-05-15 IFP Energies Nouvelles Procede de preparation d'un catalyseur mettant en oeuvre une etape de sechage rapide et son utilisation pour la synthese fischer-tropsch
WO2014028543A1 (en) 2012-08-13 2014-02-20 Array Biopharma Inc. Arry-520 for use in treating cancer in a patient with low aag
EP3030236A1 (de) 2013-08-08 2016-06-15 Array Biopharma, Inc. Filanesib, kombiniert mit pomalidomid für verbesserte antitumorwirkung
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) * 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
US10485880B2 (en) 2014-12-15 2019-11-26 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
JP6971858B2 (ja) 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CN108025086A (zh) 2015-06-23 2018-05-11 拜耳制药股份公司 Ksp抑制剂与抗b7h3抗体的抗体-活性物质缀合物(adc)
EP3313521A1 (de) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
AU2016282724A1 (en) * 2015-06-23 2018-01-18 Bayer Pharma Aktiengesellschaft Targeted conjugates of KSP inhibitors
CA3003611C (en) 2015-11-04 2022-11-01 Omeros Corporation Solid state forms of a pde10 inhibitor
CN109310781B (zh) 2016-06-15 2024-06-18 拜耳制药股份公司 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc)
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
MX2020013832A (es) 2018-06-18 2021-03-25 Bayer Ag Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025096684A1 (en) * 2023-10-30 2025-05-08 University Of Health Sciences And Pharmacy In St. Louis Err modulators
WO2025096683A1 (en) * 2023-10-30 2025-05-08 University Of Health Sciences And Pharmacy In St. Louis Err modulators
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2702803A (en) 1954-04-12 1955-02-22 Lilly Co Eli Substituted heterodiazoles
SU1065410A1 (ru) * 1982-05-07 1984-01-07 Днепропетровский Ордена Трудового Красного Знамени Химико-Технологический Институт Им.Ф.Э.Дзержинского Способ получени 2-амино-5-трет-алкил-1,3,4-тиадиазолов
EP0217519B1 (de) 1985-08-31 1992-02-05 FISONS plc 5-gliedrige heterocyclische Angiotensin-Umwandlungsenzym-Inhibitoren
US4762072A (en) * 1986-10-07 1988-08-09 Westinghouse Electric Corp. Desk and space dividing wall panel assembly
GB8625774D0 (en) 1986-10-28 1986-12-03 Reckitt & Colmann Prod Ltd Thiadiazole derivative
JPH0572686A (ja) 1991-09-11 1993-03-26 Konica Corp ハロゲン化銀写真感光材料
AU4288293A (en) 1992-04-27 1993-11-29 E.I. Du Pont De Nemours And Company Fungicidal 1,3,4-oxadiazines and 1,3,4-thiadiazines
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
JPH10513443A (ja) 1995-02-02 1998-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ＨＴ▲下２ｃ▼レセプターアンタゴニスト活性を有する複素環化合物
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
HRP980093A2 (en) 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
PL348305A1 (en) 1997-12-16 2002-05-20 Warner Lambert Co Novel amines as pharmaceutical agents
US6235762B1 (en) 1998-11-23 2001-05-22 American Cyanamid Company 2-aryl-Δ2-1,3,4-(oxa and thia)diazoline insecticidal and acaricidal agents
JP2000159756A (ja) 1998-11-23 2000-06-13 American Cyanamid Co ２―アリ―ル―δ２―１，３，４―（オキサおよびチア）ジアゾリン殺虫および殺ダニ剤
US6545030B1 (en) * 1999-01-13 2003-04-08 Warner-Lambert Company 1-heterocycle substituted diarylamines
US20020002193A1 (en) 1999-03-25 2002-01-03 Yu Dingwei Tim Thiadiazole antifungal agents
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2001056994A1 (en) 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
US20040248950A1 (en) 2001-08-24 2004-12-09 Natsuki Ishizuka Apo ai expression accelerating agent
ATE480527T1 (de) * 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
JP4399269B2 (ja) * 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
AU2003246551A1 (en) 2002-06-25 2004-01-06 Dieter Borner Assembly for recording the use of rds radio receivers
US7294643B2 (en) * 2002-11-22 2007-11-13 Board Of Regents, The University Of Texas System UK-1 analogues: methods of preparation and use
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
ES2394850T3 (es) 2003-04-18 2013-02-06 Kyowa Hakko Kirin Co., Ltd. Inhibidor de cinesina mitótica
EP1620412A2 (de) 2003-05-02 2006-02-01 Rigel Pharmaceuticals, Inc. Heterocyclische verbindungen und deren hydroisomere
US7115642B2 (en) 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
US20050009877A1 (en) 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
WO2004111023A1 (ja) 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン－１－オキシド誘導体
US20070112044A1 (en) * 2003-10-10 2007-05-17 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
JP2005232016A (ja) 2004-02-17 2005-09-02 Kyowa Hakko Kogyo Co Ltd オキサジアゾリン誘導体
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
US7723365B2 (en) * 2004-08-18 2010-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
FR2876586B1 (fr) 2004-10-20 2007-10-12 Persee Medica Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent
JP2008150291A (ja) * 2005-03-22 2008-07-03 Kyowa Hakko Kogyo Co Ltd 乾癬治療剤
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
JP2008137893A (ja) * 2005-03-22 2008-06-19 Kyowa Hakko Kogyo Co Ltd 関節炎治療剤
JP2006265107A (ja) * 2005-03-22 2006-10-05 Kyowa Hakko Kogyo Co Ltd 緑内障治療剤
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) * 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
EP2081918A2 (de) 2006-10-03 2009-07-29 Array Biopharma, Inc. Inhibitoren von mitotischem kinesin und verfahren zu deren anwendung
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2014028543A1 (en) 2012-08-13 2014-02-20 Array Biopharma Inc. Arry-520 for use in treating cancer in a patient with low aag
EP3030236A1 (de) 2013-08-08 2016-06-15 Array Biopharma, Inc. Filanesib, kombiniert mit pomalidomid für verbesserte antitumorwirkung

Also Published As

Publication number Publication date
US20080182992A1 (en) 2008-07-31
NO20072558L (no) 2007-07-18
US8236825B2 (en) 2012-08-07
CN102532051A (zh) 2012-07-04
US10017482B2 (en) 2018-07-10
JP2008516982A (ja) 2008-05-22
JP2014139249A (ja) 2014-07-31
PL1809280T3 (pl) 2011-12-30
ZA200703168B (en) 2008-06-25
US20140094603A1 (en) 2014-04-03
NZ554306A (en) 2010-12-24
PT1809280E (pt) 2011-11-15
RU2426729C2 (ru) 2011-08-20
CN103951633B (zh) 2017-05-10
WO2006044825A3 (en) 2006-10-05
AU2005295403A1 (en) 2006-04-27
US20170066733A1 (en) 2017-03-09
BRPI0518228A (pt) 2008-11-04
CY1112238T1 (el) 2015-12-09
JP5911909B2 (ja) 2016-04-27
BRPI0518228B8 (pt) 2021-05-25
RU2007118632A (ru) 2008-11-27
CN101083988A (zh) 2007-12-05
IL219857A0 (en) 2012-06-28
US20120270803A1 (en) 2012-10-25
WO2006044825A2 (en) 2006-04-27
EP1809280B1 (de) 2011-09-07
CN103626720B (zh) 2016-11-16
SI1809280T1 (sl) 2011-11-30
RS52037B (sr) 2012-04-30
ES2370774T3 (es) 2011-12-22
EP1809280A2 (de) 2007-07-25
JP2012233012A (ja) 2012-11-29
IL182417A0 (en) 2007-07-24
US20180334441A1 (en) 2018-11-22
TW200621736A (en) 2006-07-01
US20150210658A1 (en) 2015-07-30
CN103626720A (zh) 2014-03-12
CA2584866C (en) 2014-09-23
HK1106131A1 (en) 2008-03-07
CA2952920A1 (en) 2006-04-27
US7449486B2 (en) 2008-11-11
US7956073B2 (en) 2011-06-07
AU2005295403B2 (en) 2011-05-19
US20060100161A1 (en) 2006-05-11
JP5757666B2 (ja) 2015-07-29
US9499503B2 (en) 2016-11-22
CA2852516C (en) 2015-06-02
CA2868912A1 (en) 2006-04-27
US20110201651A1 (en) 2011-08-18
TWI357900B (en) 2012-02-11
ME01950B (me) 2012-04-30
MX2007004547A (es) 2007-06-07
DK1809280T3 (da) 2011-10-31
HRP20110764T1 (hr) 2011-12-31
EP1809280A4 (de) 2009-10-21
CN103951633A (zh) 2014-07-30
KR20070084348A (ko) 2007-08-24
JP5128283B2 (ja) 2013-01-23
JP2015129191A (ja) 2015-07-16
BRPI0518228B1 (pt) 2020-10-20
US9102639B2 (en) 2015-08-11
US8623895B2 (en) 2014-01-07
NO341725B1 (no) 2018-01-08
KR101280755B1 (ko) 2013-07-08
CA2868912C (en) 2017-01-03
CA2584866A1 (en) 2006-04-27
CA2852516A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
TW200510416A (en) P38 inhibitors and methods of use thereof
IL186707A (en) Mitotic quinine inhibitors and medical preparations containing them
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE537826T1 (de) Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
TW200633980A (en) Pyridones useful as inhibitors of kinases
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE450256T1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
NO20065762L (no) Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
UA98926C2 (ru) Ингибитор митотических кинезинов и его использование
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA86051C2 (en) Substituted quinoline compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809280

Country of ref document: EP